Clinical assessment of a chemosensitivity assay as a treatment planning tool for dogs with cancer

This study evaluated the clinical utility of a commercially available chemo sensitivity assay. In the first part of the study, tumor tissues from dogs with various malignancies were tested, and the dogs were treated with a mit oxantrone/cyclophosphamide combination protocol. Tumor response was evaluat ed and compared to the predicted response. Assay results were not a signifi cant predictor of clinical response to chemotherapy or of survival time. In the second part of the study, assay results were used to direct therapy in dogs with refractory lymphoma. There was no significant correlation (p equ als 0.323) between predicted response and case outcome.